Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.72 |
| ▸ | DHFR | P00374 | 2/20 | 0.48 |
| ▸ | DCPS | Q96C86 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737410 | 1.00 | MCHR1 (0.72) | MCHR1DHFRDCPSKDM4ELMNA | |
| SCHEMBL13739679 | 0.87 | MCHR1 (0.55) | MCHR1KDM4ELMNAHTTMEN1 | |
| SCHEMBL5884451 | 0.84 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL15398749 | 0.81 | MCHR1 (0.53) | MCHR1KDM4ELMNAHTTMEN1 | |
| SCHEMBL15398746 | 0.81 | MCHR1 (0.53) | MCHR1KDM4ELMNAHTTMEN1 | |
| SCHEMBL15400315 | 0.81 | MCHR1 (0.49) | MCHR1DHFRDCPSKDM4ELMNA | |
| SCHEMBL15399476 | 0.81 | MCHR1 (0.49) | MCHR1DHFRDCPSKDM4ELMNA | |
| SCHEMBL15400314 | 0.81 | MCHR1 (0.49) | MCHR1DHFRDCPSKDM4ELMNA | |
| SCHEMBL15399473 | 0.81 | MCHR1 (0.49) | MCHR1DHFRDCPSKDM4ELMNA | |
| SCHEMBL17641054 | 0.81 | MCHR1 (0.68) | MCHR1KDM4ELMNAHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678329-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8889704-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140005213-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2678329-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012154274-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005213-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | MCHR1 1613/4885DHFR 2767/4885DCPS 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.